The frequency of dermatological side effects will vary depending on the exact treatment used and, less commonly, the type of tumour. Toxicities resulted from chemotherapies. These occurrences are noteworthy because they have a psychosocial impact, as well as morbid and financial implications, and may result in the cessation or discontinuation of systemic antineoplastic therapy. Despite the fact that most dermatological AEs are classed as grade 1 or 2, their chronicity, presence on cosmetically sensitive areas, and correlation with pruritus and pain symptoms necessitate the use of preventative or reactive therapy. Indeed, the unfavourable impact of dermatological adverse events from targeted therapies on quality of life is enormous, even greater than the impact of dermatological adverse events from cytotoxic medicines. As a result of the acneiform rash caused by epidermal growth factor receptor inhibitors, 76 percent and 32 percent of oncologists have reported dose interruptions and discontinuations, respectively. Chemical stress and the usage of alcohol-free skin moisturisers are two general preventive measures (skin irritants, solvents or disinfectants). Any predisposing cause should be treated before starting therapy, hence a podiatric or foot care professional evaluation is recommended. In patients treated with sorafenib, urea emollients dramatically reduced the incidence of all-grade HFSR, delayed the time to first occurrence, and improved quality of life, and are thus recommended. In the case of hand-foot syndrome, urea emollients are also advised.

Submit the manuscript https://www.imedpub.com/submissions/skin-diseases-skin-care.html or send it as an e-mail attachment to skindiseases@eclinmed.com

With Regards
Angelina
Journal Coordinator
Skin Diseases and Skin Care